Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy · Delayed Price · Currency is EUR 46.70
+0.28 (0.60%)
At close: Jan 22, 2026
Recordati Industria Chimica e Farmaceutica Employees
As of December 31, 2024, Recordati Industria Chimica e Farmaceutica had 4,583 total employees, including 4,495 full-time and 88 part-time employees. The number of employees increased by 128 or 2.87% compared to the previous year.
Employees
4,583
Change (1Y)
128
Growth (1Y)
2.87%
Revenue / Employee
€562,820
Profits / Employee
€89,093
Market Cap
9.50B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 4,583 | 128 | 2.87% | 4,495 | 88 |
| Dec 31, 2023 | 4,455 | 86 | 1.97% | 4,455 | 0 |
| Dec 31, 2022 | 4,369 | 66 | 1.53% | 4,369 | 0 |
| Dec 31, 2021 | 4,303 | -183 | -4.08% | 4,303 | 0 |
| Dec 31, 2020 | 4,486 | 163 | 3.77% | 4,405 | 81 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Amplifon | 15,070 |
| GPI S.p.A. | 7,656 |
| Safilo Group | 3,645 |
| DiaSorin | 3,271 |
| Garofalo Health Care | 2,708 |
| EL.En. | 2,080 |
| Svas Biosana | 327 |
| Talea Group | 240 |
Recordati Industria Chimica e Farmaceutica News
- 7 days ago - Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Presents at 44th Annual J.P. - Seeking Alpha
- 9 days ago - Recordati Launches Isturisa In Canada For Cushing's Disease - Nasdaq
- 2 months ago - Recordati SpA (RICFY) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - GuruFocus
- 2 months ago - Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Amarin outlines accelerated path to positive free cash flow in 2026 supported by Recordati partnership and $70M OpEx savings - Seeking Alpha
- 6 months ago - Amarin targets $70M cost savings and accelerates VAZKEPA European expansion through Recordati partnership - Seeking Alpha
- 6 months ago - Italy's Recordati CEO sees rare disease drugs exempt from U.S. tariffs - Reuters
- 6 months ago - Five years after COVID, pharma shares languish in US policy limbo - Reuters